+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768047
  • Report
  • 62 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Cinven Ltd
  • Corcept Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Ipsen SA
  • Novartis AG
  • MORE
The global clinical trial report- “2019 Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Pituitary ACTH Hypersecretion (Cushing Disease). It presents in-depth analysis of Pituitary ACTH Hypersecretion (Cushing Disease) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Pituitary ACTH Hypersecretion (Cushing Disease).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Pituitary ACTH Hypersecretion (Cushing Disease) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Pituitary ACTH Hypersecretion (Cushing Disease)

The research work is prepared through extensive and continuous research on Pituitary ACTH Hypersecretion (Cushing Disease) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Pituitary ACTH Hypersecretion (Cushing Disease) patients are identified
  • The report includes panorama of Pituitary ACTH Hypersecretion (Cushing Disease) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Pituitary ACTH Hypersecretion (Cushing Disease) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Cinven Ltd
  • Corcept Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Ipsen SA
  • Novartis AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Region
2.2.2 Average Enrollment of Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Pituitary ACTH Hypersecretion (Cushing Disease) Treatment, 2019

3. Region wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials
3.1 Asia Pacific Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Country
3.2 Europe Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Country
3.3 North America Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Country
3.4 Middle East and Africa Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Country
3.5 South and Central America Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Country

4. Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trial Trends
4.1 Start Year wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials
4.2 Phase wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials
4.3 Trial Status wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials
4.4 Trial Type wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials

5. Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment Trends
5.1 Average Enrollment in Pituitary ACTH Hypersecretion (Cushing Disease) Trials by Year
5.2 Average Enrollment in Pituitary ACTH Hypersecretion (Cushing Disease) Trials by Phase
5.3 Average Enrollment in Pituitary ACTH Hypersecretion (Cushing Disease) Trials by Status
5.4 Average Enrollment in Pituitary ACTH Hypersecretion (Cushing Disease) Trials by Type of Trial

6. Companies Participating in Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials
6.1 Pituitary ACTH Hypersecretion (Cushing Disease) Trials by Sponsor Type
6.2 Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Pituitary ACTH Hypersecretion (Cushing Disease) Trials- Phase 1
7.2 Pituitary ACTH Hypersecretion (Cushing Disease) Trials- Phase 2
7.3 Pituitary ACTH Hypersecretion (Cushing Disease) Trials- Phase 3
7.4 Pituitary ACTH Hypersecretion (Cushing Disease) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Figure 7: North America - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Figure 9: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Phase
Figure 10: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Trial Status
Figure 11: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Type
Figure 12: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Sponsor Type
Figure 13: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials by Leading Sponsors
Figure 14: Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Phase
Figure 15: Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Trial Status
Figure 16: Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Type
Figure 17: Pituitary ACTH Hypersecretion (Cushing Disease)- Average Enrolment by Type of Sponsors
Figure 18: Pituitary ACTH Hypersecretion (Cushing Disease)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Table 5: Europe - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Table 7: North America - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Pituitary ACTH Hypersecretion (Cushing Disease) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Phase
Table 15: Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Trial Status
Table 16: Pituitary ACTH Hypersecretion (Cushing Disease) Average Enrollment by Type
Table 17: Pituitary ACTH Hypersecretion (Cushing Disease)- Average Enrolment by Type of Sponsors
Table 18: Pituitary ACTH Hypersecretion (Cushing Disease)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alder Biopharmaceuticals Inc
  • Aspireo Pharmaceuticals Ltd
  • Cinven Ltd
  • Corcept Therapeutics Inc
  • Cyclacel Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Ipsen SA
  • Laboratoire HRA Pharma SAS
  • Novartis AG
  • Strongbridge Biopharma plc
Note: Product cover images may vary from those shown
Adroll
adroll